Statera Biopharma (STAB) Competitors $0.0001 0.00 (0.00%) As of 07/16/2025 03:32 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock STAB vs. SCPS, EVLO, CMRA, GNCAQ, GNCA, ARDS, AMPE, EFTR, HSTO, and ONCSQShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Its Competitors Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Ampio Pharmaceuticals eFFECTOR Therapeutics Histogen OncoSec Medical Statera Biopharma (NASDAQ:STAB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability. Is STAB or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Scopus BioPharma N/A N/A N/A Does the media favor STAB or SCPS? In the previous week, Statera Biopharma had 3 more articles in the media than Scopus BioPharma. MarketBeat recorded 3 mentions for Statera Biopharma and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 beat Statera Biopharma's score of -1.66 indicating that Scopus BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Statera Biopharma Very Negative Scopus BioPharma Neutral Which has better earnings & valuation, STAB or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Which has more risk and volatility, STAB or SCPS? Statera Biopharma has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. SummaryStatera Biopharma beats Scopus BioPharma on 2 of the 3 factors compared between the two stocks. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5K$753.22M$5.51B$9.31BDividend YieldN/A4.84%4.25%4.09%P/E RatioN/A1.4328.1819.72Price / SalesN/A25.51439.19110.06Price / CashN/A19.5635.5357.53Price / BookN/A6.608.235.67Net IncomeN/A-$4.53M$3.23B$257.51M7 Day PerformanceN/A0.25%-0.61%-0.16%1 Month PerformanceN/A1.56%6.63%9.89%1 Year PerformanceN/A-0.43%27.07%15.08% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020News CoverageNegative NewsSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/AN/AN/A-99.8%$5KN/A0.0030AMPEAmpio PharmaceuticalsN/A$0.00-32.5%N/A-88.9%$3KN/A0.0020Gap DownEFTReFFECTOR Therapeutics0.0786 of 5 stars$0.00flatN/AN/A$1KN/A0.0010Gap DownHSTOHistogenN/A$0.00-33.3%N/A-83.3%$1K$19K0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040 Related Companies and Tools Related Companies Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Ampio Pharmaceuticals Competitors eFFECTOR Therapeutics Competitors Histogen Competitors OncoSec Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STAB) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STAB Stock Alerts